RavenQuest BioMed Inc.
RVVQF
$0.00
$0.000.00%
| 07/31/2019 | 04/30/2019 | 01/31/2019 | 10/31/2018 | 07/31/2018 | |
|---|---|---|---|---|---|
| Revenue | 305.46% | 1.72% | -53.42% | -220.24% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 305.46% | 1.72% | -53.42% | -220.24% | -- |
| Cost of Revenue | 1,662.28% | 780.27% | -241.61% | -57.16% | -- |
| Gross Profit | 176.99% | -123.72% | 142.51% | -1,310.26% | -- |
| SG&A Expenses | -7.49% | -51.80% | 72.09% | 932.65% | 1,409.91% |
| Depreciation & Amortization | 2,023.51% | 11,548.39% | 57,780.00% | 705,550.00% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.58% | -17.30% | 53.16% | 1,096.72% | 1,440.32% |
| Operating Income | -11.40% | 21.28% | -114.38% | -1,495.09% | -1,339.86% |
| Income Before Tax | 3.67% | 10.77% | -197.14% | -685.32% | -737.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 3.67% | 10.77% | -197.14% | -665.92% | -737.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 3.67% | 10.77% | -197.17% | -665.92% | -737.16% |
| EBIT | -11.40% | 21.28% | -114.38% | -1,495.09% | -1,339.86% |
| EBITDA | 19.42% | 36.87% | -45.79% | -1,020.22% | -- |
| EPS Basic | 22.44% | 33.01% | -89.29% | -200.56% | -151.49% |
| Normalized Basic EPS | 8.18% | 32.82% | -79.73% | -730.65% | -381.82% |
| EPS Diluted | 22.44% | 33.01% | -89.29% | -200.56% | -151.49% |
| Normalized Diluted EPS | 8.18% | 32.82% | -79.73% | -730.65% | -381.82% |
| Average Basic Shares Outstanding | 24.34% | 33.26% | 56.16% | 154.72% | 231.81% |
| Average Diluted Shares Outstanding | 24.34% | 33.26% | 56.16% | 154.72% | 231.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
